ATTENTION_2A: ATTENTION, figure 2A

In raredd/kmdata: A Database of Reconstructed Individual Patient Level Data from Oncology Clinical Trials

ATTENTION, figure 2A

Description

Kaplan-Meier digitized data from ATTENTION, figure 2A (PMID 26153496). A reported sample size of 460 for a primary endpoint of OS in lung cancer.

Usage

ATTENTION_2A

Format

A data frame of 307 observations and 3 variables:

	time	event time (in months)
	event	OS event indicator (0: no event, 1: event)
	arm	treatment arms (placebo, tivantinib)

Source

Yoshioka H, Azuma K, Yamamoto N, et al. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Ann Oncol 2015; 26: 2066–72.

Examples

summary(ATTENTION_2A)

kmplot(ATTENTION_2A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.